Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ogi-Keishi-Gomotsu-To-Ka-Kojin (OKGK) is a Japanese traditional Kampo medicine derived from the classical formula Ogi-Keishi-Gomotsu-To with the addition of Kojin (Red Ginseng). It is primarily recognized for its antihyperlipidemic properties, particularly in models of secondary hyperlipidemia. The medicine's mechanism of action involves the restoration and enhancement of lipoprotein lipase (LPL) activity in both postheparin plasma and cardiac tissue. By increasing LPL activity, OKGK promotes the catabolism of triglyceride-rich lipoproteins, including chylomicrons and very low-density lipoproteins (VLDL), effectively lowering elevated serum cholesterol and triglyceride levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ogi-Keishi-Gomotsu-To-Ka-Kojin.